Next Article in Journal
The Effect of Mushroom Dietary Fiber on the Gut Microbiota and Related Health Benefits: A Review
Next Article in Special Issue
Targeting Mosquitoes through Generation of an Insecticidal RNAi Yeast Strain Using Cas-CLOVER and Super PiggyBac Engineering in Saccharomyces cerevisiae
Previous Article in Journal
Phenotypic Investigation of Virulence Factors, Susceptibility to Ceragenins, and the Impact of Biofilm Formation on Drug Efficacy in Candida auris Isolates from Türkiye
Previous Article in Special Issue
Production of Phenylacetylcarbinol via Biotransformation Using the Co-Culture of Candida tropicalis TISTR 5306 and Saccharomyces cerevisiae TISTR 5606 as the Biocatalyst
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JoF
Volume 9
Issue 10
10.3390/jof9101027
jof-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Advances in Metabolic Engineering of Pichia pastoris Strains as Powerful Cell Factories

by
Jian Zha
*,
Dan Liu
,
Juan Ren
,
Zhijun Liu
and
Xia Wu
*
School of Food and Biological Engineering, Shaanxi University of Science and Technology, Xi’an 710021, China
*
Authors to whom correspondence should be addressed.
J. Fungi 2023, 9(10), 1027; https://doi.org/10.3390/jof9101027
Submission received: 28 August 2023 / Revised: 11 October 2023 / Accepted: 16 October 2023 / Published: 19 October 2023
(This article belongs to the Special Issue Development and Utilization of Yeast Resources)
Browse Figures
Review Reports Versions Notes

Abstract

:
Pichia pastoris is the most widely used microorganism for the production of secreted industrial proteins and therapeutic proteins. Recently, this yeast has been repurposed as a cell factory for the production of chemicals and natural products. In this review, the general physiological properties of P. pastoris are summarized and the readily available genetic tools and elements are described, including strains, expression vectors, promoters, gene editing technology mediated by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9, and adaptive laboratory evolution. Moreover, the recent achievements in P. pastoris-based biosynthesis of proteins, natural products, and other compounds are highlighted. The existing issues and possible solutions are also discussed for the construction of efficient P. pastoris cell factories.

1. Introduction

Methylotrophic yeasts are microorganisms capable of utilizing methanol as the sole source of carbon and energy and are hence considered as potential hosts for green bio-manufacturing. Meanwhile, these microbes, when used as cell factories, have some other advantages such as high fermentation density, low accumulation of toxic metabolites, ability to grow in cheap basal salt media, and capability of complete protein modifications and processing.
Pichia pastoris, which has been renamed as Komagataella phaffii [1], is one of the typical methylotrophic yeasts and plays an important role in the production of recombinant proteins. Using the P. pastoris expression system, thousands of recombinant proteins have been synthesized so far, some of which have successfully entered the market, such as human insulin and human interferon-α [2].
P. pastoris is a unicellular microorganism with the advantages of high expression levels of recombinant proteins, ease of large-scale cultivation, and low cultivation costs [3]. Its cell density can reach 130 g/L during industrial production [4], and the yield of recombinant proteins can reach tens of grams per liter [5]. Recombinant proteins can be expressed both intracellularly and in a secreted form in P. pastoris. The efficiency of secretory expression in P. pastoris is generally higher than that in Saccharomyces cerevisiae, which is another commonly adopted workhorse for microbial bio-production [6]. P. pastoris has a clear genetic background and is excellent in protein folding and post-translational modifications, especially glycosylation [7,8]. In P. pastoris, oligosaccharide chains added to proteins after translation (8–14 mannose residues per side chain) are shorter than in S. cerevisiae (50–150 mannose residues), and O-linked glycosylation is very minimal, potentially avoiding the risk of excessive glycosylation (Figure 1) [9]. Moreover, P. pastoris contains a strong methanol utilization pathway and is able to provide some key cofactors [10]. Another major difference between these two yeasts is that the homologous recombination (HR) pathway in P. pastoris is significantly weaker than the non-homologous end joining (NHEJ) pathway [11]. In recent years, genetic and metabolic modifications of P. pastoris have been expanded and deepened attributed to gene editing tools, promoter engineering approaches such as promoter mutation libraries and synthetic core promoters, novel metabolic engineering strategies such as metabolic compartmentalization and cofactor engineering, and other techniques. Additionally, information on metabolic processes and strain physiology has gradually been revealed via systems biology and omics studies [12,13], which greatly benefits the biosynthesis of natural products in this organism. In this review, we introduce the physiological characteristics of P. pastoris, summarize the latest advances in this expression system, and list its practical applications in the production of recombinant proteins and value-added compounds.

2. Physiological Characteristics of Pichia pastoris

P. pastoris belongs to the Ascomycetes class [14]. Its colony is generally milk-white with a smooth surface, showing a bulge (Figure 2). This yeast mainly exists in the haploid form in the asexual growth phase. Under nutrient limitation, two haploid cells can be induced with different physiological types to mate and fuse into diploids [15].
P. pastoris grows optimally at 28–30 °C [16] with a tolerance of pH ranging from 3 to 7 [17]. The carbon source includes a variety of compounds such as glucose [18], glycerol [19], L-rhamnose [20], formate [21], and so on. This microbe can also use methanol as its sole source of carbon and energy owing to the presence of enzymes in the peroxisomes essential to methanol metabolism, such as alcohol oxidase, dihydroxyacetone synthase, and peroxidase [22]. Among these, the expression of alcohol oxidase is strictly induced and controlled by methanol, so the enzyme activity can only be detected in the presence of methanol [23]. P. pastoris can use ammonium sulfate, proline, and peptone as the nitrogen source. When ammonium sulfate is adopted, the expression levels of major genes related to methanol utilization (gene MUT) and peroxisome biogenesis/degradation (gene PEX) are the highest [24]. Meanwhile, an appropriate NH4+ concentration is beneficial for cell growth and heterologous protein expression [24,25]. In some cases, the use of complex nitrogen sources such as casamino acids and peptone can effectively alleviate proteolytic degradation of heterologous proteins [26].

3. The Pichia pastoris Expression System

3.1. Strains

At present, the commonly used P. pastoris strains for heterologous protein expression include X-33, GS115, KM71, SMD1163, and MC100-3. The characteristics of these strains have been described in detail in other reports [27,28]. Based on their ability to utilize methanol, P. pastoris strains are mainly divided into three phenotypes, i.e., Mut+, MutS, and Mut−. Strain X-33 is a wild-type strain carrying genes AOX1 and AOX2 (both encoding alcohol oxidase) and the phenotype is Mut+ (methanol utilization plus), which is often used to express recombinant plasmids containing zeocin resistance. Both GS115 and KM71 strains are histidine deficient. The GS115 strain contains AOX1 and AOX2, and its own phenotype is Mut+. In comparison, the KM71 strain is MutS (methanol utilization slow) because the gene AOX1 is replaced by the S. cerevisiae Arg4, and the strain can only utilize methanol at a slower rate dependent on the weakly controlled gene AOX2. Strain MC100-3 is deficient in both AOX genes and hence cannot grow on methanol, thus performing the Mut− (methanol utilization minus) phenotype. SMD1163 is a protease deficient strain in which the pep4 gene encoding protease A and the prb1 gene encoding a subtilisin-like protease are knocked out. This strain is favorable for the expression of heterologous proteins sensitive to proteases [29].
Dozens of P. pastoris strains, including X-33 and GS115, have been compared genomically and transcriptomically to analyze why recombinant protein expression in these strains is different [30]. Genomic analysis shows that there are functional and non-functional single-nucleotide polymorphisms in the genome sequences of different strains, which affect DNA repair, cell cycle, cell wall structure and so on. Transcriptomic analysis shows that there are variations in the expression levels of genes involved in the pentose phosphate pathway, methanol utilization pathway, and other pathways in different strains under different growth conditions. Compared with other strains, the higher transformation efficiency and better protein secretion for strains X-33 and GS115 may be due to the higher permeability of their cell wall, which has been a focus of current studies [30].

3.2. Expression Vectors

According to the location of the expressed proteins, P. pastoris vectors can be divided into intracellular expression vectors (such as pPIC3, pPICZ, pPHIL-D2, etc.) and secretory expression vectors (such as pPIC9, pPIC9K, pPICZα, etc.), in which the secretory expression vector usually contains a signal peptide sequence inserted behind the promoter. The characteristics of the expression vectors commonly used at present are summarized in detail in a recent report [31].
Integrative plasmids are frequently used for exogenous gene expression in P. pastoris. Such vectors are typically constructed as E. coli/P. pastoris shuttle vectors. On the one hand, these vectors contain elements for plasmid amplification in E. coli, including an origin of replication and a selection marker, which is usually antibiotic resistance. On the other hand, these vectors carry components required for heterologous gene expression in P. pastoris, including the promoter/terminator, the multiple cloning site, and a proper selection marker. The selection marker can be an auxotrophic marker (HIS4, ARG4, URA3, etc.) or an antibiotic resistance marker (zeocin, G418, etc.).
To introduce a foreign gene into P. pastoris, episomal vectors are generally accompanied with easier manipulation and higher efficiency compared with gene integration into the chromosome. However, natural autoreplicative vectors have limited applications in P. pastoris due to their instability and the uneven distribution among progeny cells during cell division. To solve these issues, the genome of P. pastoris has been analyzed and the chromosome-2 centromeric DNA sequence has been identified to facilitate stable autoreplication and accurate distribution of the plasmid [32]. The stability of the episomal vectors can also be improved by introducing the autonomously replicating sequences (ARS) from other organisms, such as the panARS derived from Kluyveromyces lactis [33].

3.3. Promoters

3.3.1. AOX1 Promoter

Upon entry into P. pastoris, methanol is decomposed into formaldehyde and hydrogen peroxide by alcohol oxidase encoded by AOX1 and AOX2. However, the enzyme activity is mostly provided by AOX1 due to the low expression level of AOX2 [23]. The endogenous promoter controlling AOX1 expression, i.e., PAOX1 upstream of AOX1, can be efficiently induced by methanol at low concentrations, with the optimal concentration ranging from 0.5% to 2.0% [6].
In recent years, with the continuous mechanistic research on the transcriptional regulation of PAOX1, the cis-acting elements and transcription factors that affect the transcriptional activity of this promoter have been discovered. Inan et al. divided PAOX1 into five segments (A~E), of which fragments B and E play a promotional role for AOX1 expression (Figure 3A) [34]. In P. pastoris, the response of PAOX1 to methanol is positively regulated by a cascade of transcription factors including Mit1, Mxr1, and Prm1, which bind to different sites of PAOX1 [35]. Among them, Mxr1 is closely related to the carbon-source-induced repression of PAOX1. When methanol is used as the carbon source, Mxr1 is transferred from the cytoplasm to the nucleus, leading to the derepression of PAOX1. At this point, Prm1 activates its own expression and the expression of Mit1, thus inducing strong activation of PAOX1. The strength of PAOX1 can be improved via Mit1 overexpression [36]; however, Mit1 exerts feedback inhibition of Prm1 expression (Figure 3B) [37]. In consequence, the expression level of Mit1 needs to be delicately tuned to achieve the optimal expression of genes controlled by PAOX1.

3.3.2. GAP Promoter

Inducible promoters generally have some intrinsic disadvantages, such as costs and toxicity associated with the inducers and concerns of leaky expression of the target genes. A preferred alternative is the constitutive promoter. Genes regulated by constitutive promoters can be normally expressed during cell growth without the involvement of inducers. In P. pastoris, the most commonly used constitutive promoter is the glyceraldehyde-3-phosphate dehydrogenase promoter (PGAP), which is considered as a standard promoter for methanol-free expression systems [38,39]. This promoter is regulated by the metabolism of carbon sources, and its transcription level is the highest in the presence of glucose and is the lowest when cells are fed with methanol [40]. In a study on the recombinant expression of renal peptide transporter rPEPT2 in P. pastoris using PGAP, the expression level of rPEPT2 was about 5-fold higher in glucose than in methanol [41].
PGAP is generally weaker than PAOX1 and attempts have hence been made to improve the strength of PGAP. Ata et al. [42] analyzed the transcription factor binding sites of PGAP. Via targeted deletion or overexpression of these sites, a promoter library was constructed with different strength in initiating gene expression. Moreover, a GAL4-like transcription factor was found to be critical in regulating the strength of PGAP and its overexpression could significantly improve the production of heterologous proteins controlled by PGAP [42]. This transcription factor is homologous to the GAL4 transcription factor in S. cerevisiae, which is involved in the regulation of galactose utilization [43].

3.3.3. Other Promoters

Although the use of methanol as the sole source of carbon and energy is a major advantage of the P. pastoris cell factories, the toxicity and safety issues of methanol impose many limitations on practical industrial applications [44]. To solve this problem, methanol-free induction systems have been developed based on PAOX1. Chang et al. synthesized a positive feedback circuit in which PAOX2-driven Mxr1 promotes the transcription of PAOX1, while PAOX1 is induced under glycerol starvation or in the absence of carbon sources [45]. Kinases have been proposed as potential targets for regulating the repression of PAOX1 in the presence of a common carbon source such as glycerol [46]. By targeting the genes encoding glycerol kinase (gut1) and dihydroxyacetone kinase (dak), non-methanol-inducible PAOX1 expression systems were constructed using glycerol and dihydroxyacetone as carbon sources to induce PAOX1 expression, respectively, although the induction was not as efficient as that induced by methanol [47].
In addition to the above modifications of targets or transcription factors involved in the regulation of PAOX1, a large number of novel promoters suitable for the P. pastoris expression system has also been explored [48,49,50], with the recently identified promoters listed in Table 1. Among these, the promoter PADH2 is naturally present in P. pastoris to regulate the expression of the alcohol dehydrogenase gene ADH2, which is involved in the conversion of ethanol to formaldehyde. This promoter can be activated via direct interaction with the transcription factor Mxr1 [51]. By replacing the repressor region of PADH2 with the activator region, the SNT5 promoter is obtained, which is much stronger than PADH2 [51].
P. pastoris can use L-rhamnose as a sole carbon source, and its metabolism is heavily dependent on L-rhamnonate dehydratase and L-2-keto-3-deoxyrhamnonate aldolase encoded by LRA3 and LRA4, respectively [20]. The relevant endogenous promoters of these genes, i.e., PLRA3 and PLRA4, are tightly regulated by L-rhamnose, among which PLRA3 has a priming strength equivalent to that of PGAP and can efficiently drive the production of foreign proteins [20].

3.3.4. Synthetic Core Promoter Engineering

The core promoter region plays a pivotal role in the regulation of gene expression, and its genetic modification is an important content of promoter engineering. The core promoter is the region necessary for RNA polymerase to recognize and initiate transcription, and it consists of the RNA polymerase binding site, the TATA box, and the transcription start site. In P. pastoris, fully synthetic core promoters and the 5′-untranslated region have been designed and applied to PAOX1, resulting in a series of promoter libraries with different expression levels [59]. Portela et al. designed and synthesized 112 synthetic core promoter sequences according to the sequence and function relationship, nucleosome occupancy, and the existence of short motifs of the natural core promoter. The synthetic sequences were fused with the cis-regulation module upstream of P. pastoris AOX1, which significantly improved the activity of the promoter. In addition, these synthetic sequences could be used interchangeably for different core promoters without affecting the activity [60].

3.4. Signal Peptides

Secretory expression of proteins is generally dependent on cleavable signal peptides (usually 15–50 amino acids) that direct the transmembrane transfer of the newly synthesized peptides and proteins. These signal peptides, mostly located at the N-termini of the secreted proteins, usually contain three domains, i.e., the positively charged basic N-terminus (1–5 amino acids), the hydrophobic center that forms a helical structure (7–15 amino acids), and the highly polar C-terminus (3–7 amino acids) that serves as the cleavage site [61]. With a great impact on the extent of protein folding and the rate of protein secretion, signal peptides play a crucial role in high-level expression and secretion of functional proteins [62].
The signal peptides commonly used for protein secretion in P. pastoris include the signal sequence of α-factor and invertase-2 (SUC2) of S. cerevisiae, and P. pastoris acid phosphatase signal peptide (PHO1). Among these, α-factor is used most frequently and is mainly suitable for the secretory expression of peptides and small proteins. To further improve the efficiency of secretion, this signal peptide has been engineered through codon optimization, modification of the hydrophobic region, addition of spacer sequences, and site-directed mutagenesis [63,64,65]. Recently, four novel endogenous signal peptides have been discovered, including Dan 4, Gas 1, Msb 2, and Fre 2, according to the reported secretomes and genomes of P. pastoris [66]. This greatly expands the pool of signal peptides to be selected for suitable expression and secretion of recombinant proteins in P. pastoris. In addition, several signal peptides naturally present in other organisms can also be used for the expression of exogenous proteins in P. pastoris. Examples include the recombinant expression of human lysozyme in P. pastoris using the signal peptide from human serum albumin [67], and the secretory expression of Candida antarctica lipase B in P. pastoris guided by the C. antarctica lipase B signal peptide, with a higher secretion efficiency than that of α-factor [68]. However, given its importance, it is not easy to predict which signal peptide results in the best expression and secretion of the protein product, and different secretion efficiency can be achieved even in the same strain using the same signal peptide for distinct heterologous proteins.

3.5. CRISPR/Cas9 Genome Editing in Pichia pastoris

Since P. pastoris is an important workhorse for the synthesis of various bio-products, it is crucial to establish efficient and concise gene editing technologies for the genetic modifications of this microbe. Traditionally, gene insertion/deletion/replacement of P. pastoris relies on homologous recombination, which is inefficient with a low rate of success even when long homologous arms (sometimes more than 1 kb) are used. This is due to the domination of NHEJ over homologous recombination in this yeast [11]. Deletion of KU70 impairs NHEJ and significantly facilitates homologous recombination at the expense of a lower transformation efficiency and slower cell growth.
CRISPR/Cas9 introduces breaks in DNA sequences complementary to the sgRNA, which are then repaired by host cells. Thereby, genetic modifications can be introduced programmably at desired locations by using sgRNA with particularly designed sequences. Compared with traditional homologous recombination-guided genomic modification, CRISPR/Cas9 is highly flexible in the sense that only sgRNA needs to be re-designed for each independent genomic modification process. As one of the most potent and convenient gene editing technologies, CRISPR/Cas9 has been explored extensively in the engineering of P. pastoris, as reviewed elsewhere [8,69,70].
CRISPR/Cas9-mediated genomic editing in P. pastoris relies on the correct expression of Cas9 and sgRNA in the nucleus, which can be affected by a series of factors. To improve the expression, researchers used RNA Pol II promoter for sgRNA expression, added ribozyme sequences both upstream and downstream of sgRNA, and optimized the codon of Cas9. After such optimization, near 100% efficiency could be achieved in P. pastoris for gene deletion, and multiplex gene deletion and targeted gene insertion was achieved efficiently with the aid of NHEJ [71]. This system was further introduced into a KU70-knockout strain, so that DNA breaks could be repaired through homologous recombination. Despite lower cell viability, near 100% efficiency of gene integration was achieved [72]. Recently, it has been reported that high-level expression of RAD52 (radiation sensitive 52 that limits homologous recombination repair) helps to increase the single-gene editing efficiency to 90%; additionally, deletion of the MPH1 gene (mutator phenotype encoding a member of the DEAH family of proteins) can improve the efficiency of multi-fragment recombination by 13.5-fold [11]. Meanwhile, based on this efficient genome editing platform, 46 neutral sites have been identified for heterologous gene integration under various growth conditions, where the heterologous gene could be placed without affecting the basic cell metabolism [11].
The biosynthetic pathways of value-added compounds (natural products and bulk chemicals) are often complex and involve multiple pathway genes. Therefore, a competent genetic tool that can manipulate multi-gene pathways has important implications for the application of P. pastoris as a cell factory. Based on the KU70 knockout strain, a CRISPR/Cas9-mediated marker-less multi-site gene integration method has been developed, for which various sgRNA targets are designed within 100 bp upstream of the promoter or downstream of the terminator. Using this method, the integration efficiency of double-locus could reach 57.7%–70% [73]. The same method was used to establish a standardized CRISPR-based synthetic biology toolkit, in which the integration efficiency of double-locus could reach ~93% [74]. This toolkit allowed for one-step assembly of the biosynthetic pathways of 2,3-butanediol, β-carotene, zeaxanthin, and astaxanthin [74]. Meanwhile, efficient genome integration of heterologous genes has been investigated with short homology arms. The recombination mechanism of S. cerevisiae was introduced into P. pastoris by overexpressing genes related to the S. cerevisiae homologous recombination (RAD52, RAD59, SAE2, etc.), and a final 98% efficiency of double-locus integration was achieved using a homologous arm of ~40 bp [75].
Most of the existing forms of the CRISPR/Cas9 system in P. pastoris are plasmids. However, the stability and copy number of the plasmid have a certain impact on the efficiency of gene editing. Therefore, researchers have been attempting to identify replicons with high stability and appropriate copy numbers for improving the editing efficiency of the CRISPR/Cas9 system. For example, Gu et al. constructed a set of episomal plasmids containing autonomous replication sequences of different species and systematically compared their differences in transformation efficiency, copy number, and stability. The plasmid stability could be significantly enhanced when the replication origin of the plasmid, i.e., PARS1, was replaced with panARS from Kluyveromyces lactis, and the gene editing efficiency of this CRISPR/Cas9 system increased by up to 10-fold [33].

4. Adaptive Laboratory Evolution of Pichia pastoris

Adaptive laboratory evolution (ALE) is a method to artificially simulate the mutation and selection process in natural evolution under laboratory conditions such that the directed evolution of microorganisms can be achieved within a short period of time and mutated microbes with desired traits can be screened [76]. Compared with metabolic engineering, ALE only focuses on the generation of appropriate interference factors without detailed information on the intricate and intersecting metabolic networks, thus demonstrating broad applicability and strong practicability. ALE is one of the most effective methods of strain construction toward high-level synthesis of bio-products [77,78]. Although widely used in S. cerevisiae and E. coli, ALE only has limited applications in P. pastoris, and there is still a large space for development.
Efficient use of carbon sources and substrates is key to the high-level microbial production of bio-products, and ALE has been adopted in promoting the metabolic performances of P. pastoris on various nutrients or substrates. Moser et al. investigated the effect of growth media on cell growth and recombinant protein production in P. pastoris X-33 using methanol as a carbon source for continuous subculture in eutrophic medium YPM and low-nutrient medium BMM. After approximately 250 generations, evolved strains showed higher growth rates. Whole genome sequencing identified mutations in the AOX1 gene involving the methanol binding region and its vicinity, leading to, surprisingly, a decline in AOX activity, possibly due to less intracellular accumulation of the toxic compound formaldehyde. Such methanol adaptation led to significantly higher titers of recombinant human serum albumin and fused lobes hexosaminidases [79]. Similarly, adaptation of P. pastoris GS115 toward xylose utilization in a sequential batch culture improved the consumption rate of xylose after 50 generations of evolution, and the evolved strain could consume 18 g/L of xylose in 72 h, which was 25% higher than the initial strain [80].
P. pastoris is naturally a heterotrophic microbe. Excitingly, scientists converted it into an autotrophic yeast using CO2 as the sole carbon source by replacing the peroxisomal methanol utilization pathway with the CO2 fixation pathway [81]. However, the engineered strain exhibited a specific growth rate of 0.008 h−1, which was far from actual requirements. To improve cell growth, ALE was conducted using serial batch cultivations in the presence of CO2 and methanol, and the evolved strain exhibited a specific growth rate of 0.018 h−1. Further analysis of the evolved strain identified that the mutation of Nma1 (encoding nicotinic acid mononucleotide adenylyltransferase) and PRK (encoding phosphoribulokinase) genes reduced the activity of the relevant enzymes and promoted the intracellular ATP levels, thus leading to an increase in the growth rate [82].

5. Practical Applications of Pichia pastoris as a Cell Factory

Since Philips Petroleum Company released the P. pastoris expression system to academic research laboratories in 1993, the expression system has developed rapidly [83]. P. pastoris has gradually replaced S. cerevisiae as the eukaryotic expression system because it secretes very few endogenous proteins and has glycosylation similar to that in mammalian cells. P. pastoris has thus been gradually developed into a common host for the expression of medical and industrial enzymes, and thousands of recombinant proteins have been successfully produced [84]. In addition, natural products with diverse structures have also been synthesized in this host (Figure 4 and Table 2), which overcomes the disadvantages associated with chemical synthesis or extraction from plants that are traditionally used for their production. These accomplishments have promoted the engineering and development of P. pastoris as a potent and potential microbial platform [8].

5.1. Recombinant Proteins

5.1.1. Nanobodies

Nanobodies, the natural antibodies first found in the serum of camels and sharks, are the smallest units known to bind antigens [100,101]. Compared with traditional antibodies, nanobodies have unique properties such as strong antigen binding, low immunogenicity, high solubility and stability, and low molecular weight, which offer potential advantages in disease diagnosis and treatment [102]. For example, nanobody neutralization therapy has been employed in the treatment of the coronavirus COVID-19 [103]. Nanobodies can be stably expressed in P. pastoris besides prokaryotic hosts [104]. For example, nanobodies against Clostridium botulinum neurotoxin were expressed in P. pastoris, and the yield and quality obtained were higher than those produced by bacteria [105]. An antitumor nanobody was functionally expressed in P. pastoris, and the yield and the half-life were improved via fusion with human serum protein [106].
To avoid some of the drawbacks of methanol-induced systems in P. pastoris, constitutive expression for nanobody production has been developed. Chen et al. constructed the constitutive anti-CEACAM5 nanobody expression system under the control of the GAP promoter and finally obtained 51.71 mg/L of the nanobody in a shake flask with process optimization [107]. This was the first report on the expression of nanobodies under a constitutive promoter in P. pastoris, which lays the foundation for the constitutive synthesis of other nanobodies. The GAP promoter was also adopted for the functional expression of other nanobodies in P. pastoris [108].

5.1.2. Human Proteins

Proteins are essential components of human tissues and participate in a variety of essential physiological activities in the body such as maintenance of the normal metabolism and transport of various substances across membranes. Abnormal expression of proteins in the human body may cause various diseases. Therefore, these proteins become effective targets for disease treatment, and it is necessary to construct heterologous expression platforms to synthesize a large number of humanized recombinant proteins for drug screening.
Human serum albumin (HSA) is the major protein in human plasma and is widely used for drug delivery. Its recombinant expression in P. pastoris GS115 has been reported, and a high yield of 8.86 g/L was obtained after process optimization [109]. Human coagulation factor XII plays an important role in thrombosis, and its abundant supply is necessary for inhibitor screening in the development of antithrombotic drugs. The recombinant serine protease domain of human coagulation factor XII has been expressed in P. pastoris X-33 with a yield of 20 mg/L and a clotting activity similar to that of its natural counterpart [110]. Compared with these cellular proteins which can be expressed easily in the soluble form, high-level microbial expression of human membrane proteins can be a real challenge. Nonetheless, a human multichannel membrane protein named sterol ∆8-∆7 isomerase has been successfully expressed in the form of a GFP fusion in P. pastoris as well as in E. coli and S. cerevisiae, with the best expression achieved in P. pastoris at 200 mg/L in shake flasks and 1000 mg/L in condensed culture [111]. Insulin is a typical drug for the treatment of diabetes. For its expression, the codon-optimized gene encoding insulin precursor (IP) fused to the α-factor signal peptide was integrated into the genome of P. pastoris X-33. IP was produced at 3 g/L in batch fermentation using a medium containing 2 g/L methanol at a low salt and high glycerol concentration. Recombinant human insulin with a purity of 99% was obtained after IP processing and transpeptidation [112]. Further optimization of the fermentation and purification processes greatly saved time and economic costs, facilitating fast recovery of recombinant human insulin [113]. In the case of the expression of recombinant human interferon α 2b (huIFNα2b) in P. pastoris, a production titer of 436 mg/L was achieved in a 1.7 L bioreactor with medium optimization guided by the design of experiments and artificial intelligence, and the key components of the optimal medium contained 46 g/L glycerol, 10 g/L ammonium sulfate, and 1.38% (v/v) methanol. This protein was expressed with human-type N-glycosylation and presented anti-proliferative activity on breast cancer cells [114].

5.2. Value-Added Compounds

5.2.1. Terpenoids

Terpenoids are secondary metabolites with isoprene as the basic structural unit, and they mainly include monoterpenoids, sesquiterpenoids, diterpenoids, triterpenoids, and polyterpenoids [115]. Most of these compounds have anti-tumor, anti-inflammatory, and immunomodulatory effects, and are widely used in food processing and pharmaceutical manufacturing industries [116]. Yeast cells generally produce more precursors than bacteria for terpenoid biosynthesis, including DMAPP (dimethylallyl diphosphate) and IPP (isopentenyl diphosphate) [117]. Compared with other yeast chasses, P. pastoris can reach a higher fermentation density, produce fewer metabolic byproducts, and present strong tolerance to complex environments. These traits make P. pastoris suitable for terpenoid biosynthesis.
Currently, a variety of common terpenoids such as astaxanthin and β-carotene has been produced in P. pastoris, with great breakthroughs achieved recently in the biosynthesis of some other terpenoid compounds such as α-santalene, catharanthine, lycopene, and α-farnesene. The biosynthesis of α-santalene in P. pastoris was achieved for the first time by integrating the codon-optimized santalene synthase gene SAS into the chromosome of P. pastoris using CRISPR/Cas9. The production was elevated via promoter optimization for SAS expression, overexpression of key genes (tHMG1, IDI1, and ERG20) in the mevalonate (MVA) pathway, and by increasing the copy number of SAS. Combined with process optimization, the production titer of α-santalene reached 21.5 g/L in fed-batch fermentation [85].
The monoterpene indole alkaloid catharanthine is a precursor of the potent anticancer drug vincristine. This plant natural product is expensive with limited supply due to its complex structure and low abundance. Its de novo biosynthesis from methanol and mannitol has been achieved in P. pastoris via division of the entire pathway into three modules, i.e., the nepetalactol module, the strictosidine module, and the catharanthine module. These modules were integrated into the genome at optimized sites and the pathway enzymes were screened for activity and selectivity. Committed steps were identified and the corresponding genes were overexpressed with higher copy numbers. Combined with process optimization, catharanthine was produced at 2.57 mg/L in fed-batch fermentation, representing the most complicated molecule heterologously synthesized in a non-model microbe [86].
Lycopene is a kind of carotenoid with high nutritional value and its biosynthesis in engineered P. pastoris has been reported with a relatively low yield [118]. To improve the production, a recent study integrated the lycopene biosynthetic gene from Corynebacterium glutamicum ATCC 13032 into the genome of P. pastoris GS115 via homologous recombination under the control of PAOX1. Precursor supply was enhanced via genomic integration of an extra copy of HMGS and HMGR, which are critical genes in the MVA pathway. Since the generation of GGPP (geranylgeranyl diphosphate) catalyzed by GGPPS (geranylgeranyl diphosphate synthase) is a rate-limiting step, the expression of the endogenous GGPPS gene was up-regulated by integrating two copies of this gene into the genome. These efforts led to a lycopene yield of 6.146 mg/g dry cell weight in shake flasks, which is the highest for lycopene production in P. pastoris [87].
α-Farnesene is a volatile sesquiterpene with important applications in the fuel, food, and pharmaceutical industries. Its biosynthetic pathway mainly includes three modules, i.e., the acetyl-CoA biosynthetic pathway, the MVA pathway, and the terminal biosynthetic pathway of α-farnesene. In a recent study, the production of this compound in P. pastoris was promoted after an array of engineering efforts, including (i) episomal overexpression of key genes involved in the MVA pathway and α-farnesene biosynthesis, i.e., HMG1, IDI1, and ERG20; (ii) introduction of ATP-dependent citrate lyase (ACL) from Yarrowia lypolitica and pyruvate dehydrogenase (cytoPDH) from E. coli MG1655 for a higher level of cytoplasmic acetyl-CoA; (iii) introduction of the isopentenol utilization pathway (IUP) into P. pastoris peroxisomes for better accumulation of IPP and DMAPP, and (iv) co-feeding of sorbitol and oleic acid as carbon sources. These attempts led to the synthesis of 2.56 g/L α-farnesene [119]. The synthesis of α-farnesene usually requires six molecules of NADPH and nine molecules of ATP. To further improve the production, the biosynthetic pathway of these two cofactors was reprogrammed via overexpression of key enzymes in the oxidative pentose phosphate pathway and introduction of the S. cerevisiae-derived NADH kinase POS5, which catalyzes the formation of NADPH from NADH. The supply of NADPH and ATP was optimized by increasing AMP accumulation required for ATP synthesis and decreasing NADH consumption. Such engineering resulted in a yield of 3.09 g/L [88].

5.2.2. Polysaccharides

Polysaccharides widely exist in nature and participate in important cellular processes as an energy source and organizational structure. Polysaccharides can be used as efficient drug carriers due to their biodegradability, biocompatibility, and generally low costs [120]. Polysaccharide biosynthesis using engineered microorganisms has been attracting increasing attention, with some of the focus laid on P. pastoris due to its abundant supply of sugar precursors.
Hyaluronic acid (HA) is a polysaccharide with high clinical value, especially the high molecular weight HA. Microbial production of high molecular weight HA has been limited by insufficient precursor supply and cell growth inhibition [121]. To tackle this problem, the Xenopus laevis xhasA2 and xhasB genes (encoding hyaluronan synthase 2 and UDP-glucose dehydrogenase, respectively) were expressed in P. pastoris, and 1.2 MDa HA was successfully synthesized upon overexpression of the endogenous genes encoding UDP-glucose pyrophosphorylase (hasC), UDP-N-acetylglucosamine pyrophosphorylase (hasD), and phosphoglucose isomerase (hasE) [89]. Further engineering work adopted the weak AOX2 promoter in replacement of the strong AOX1 promoter to reduce the expression of hyaluronan synthase. Such an attempt increased the molecular weight of HA to 2.5 MDa with a yield of 0.8–1.7 g/L at 26 °C to alleviate growth inhibition [89].
Chondroitin sulfate is one of the main drugs for the prevention and treatment of arthritis. Microbial synthesis represents a green technology compared with extraction from animal tissues. Recently, researchers constructed the biosynthetic pathway of chondroitin sulfate in P. pastoris via a series of engineering efforts [90]. First, kfoC and kfoA from E. coli K4 and tuaD from Bacillus subtilis were introduced into P. pastoris and codon-optimized, resulting in 189.9 mg/L of chondroitin. Then, expression of active chondroitin-4-O-sulfotransferase was achieved via optimization of the promoter and the Kozak sequence, which led to the production of 182.0 mg/L of chondroitin sulfate with a sulfation degree of 1.1%. Next, the sulfation degree was elevated to 2.8% by overexpressing adenosine-5′-triphosphate sulfurylase and adenosine 5′-phosphosulfate kinase to enhance the supply of 3′-phosphoadenosine-5′-phosphosulfate. These efforts led to the production of 2.1 g/L of chondroitin sulfate from methanol with a sulfation degree of 4.0% in fed-batch fermentation.
P. pastoris can synthesize short- and low-immunogenic humanized glycosyl chains for attachment to recombinant glycoproteins, and are thus considered suitable for the biosynthesis of oligosaccharides. 2′-Fucosyllactose (2′-FL) is a major oligosaccharide in breast milk, and its application in infant formula has attracted great interest. Very recently, de novo synthesis of 2′-FL in P. pastoris has been accomplished for the first time via homologous recombination-guided integration of the genes encoding the lactose transporter Lac12 and the relevant pathway enzymes into the genome of P. pastoris under the control of the constitutive PGAP promoter. By further optimizing the fermentation conditions, 2’-FL was produced at 0.276 g/L in a 5 L bioreactor [91].

5.2.3. Polyketides

Polyketides are a class of widely distributed natural products produced during the secondary metabolism of plants or microorganisms, with rich chemical properties and unique physiological activities. Polyketide biosynthesis in P. pastoris was first reported in 2013 for the fungal polyketide compound 6-methylsalicylic acid (6-MSA) [92]. The genes encoding Aspergillus nidulans phosphopantetheinyl transferase (npgA) and Aspergillus terrus 6-MSA synthase (atX) were integrated into the genome of P. pastoris via homologous recombination, thus producing 2.2 g/L of 6-MSA in a 5 L bioreactor upon 20 h of methanol induction. On this basis, a more structurally complex polyketide citrinin was also synthesized in P. pastoris by assembling npgA, Monascus purpureus citrinin polyketide synthase gene pksCT, and several genes in the citrinin gene cluster [93]. In addition, the anti-hypercholesterolemia drug lovastatin and its precursor monacolin J were also efficiently synthesized from methanol in P. pastoris upon introduction and optimization of the pathway genes. By dividing the pathways into multiple modules and using a co-culture approach, monacolin J and lovastatin were produced at 593.9 mg/L and 250.8 mg/L, respectively [94].

5.2.4. Other Compounds

The biosynthesis of other natural products in P. pastoris has also been attempted, such as flavonoids and stilbenes. Flavonoid synthesis relies on aromatic amino acids as precursors. A dominant P. pastoris chassis for the synthesis of L-tyrosine from glycerol was constructed by overexpressing key genes in the pentose phosphate pathway or shikimate pathway. This involved integration of an extra copy of endogenous TKL1 (encoding transketolase), SOL3 (encoding 6-gluconalactonase), ZWF1 (encoding glucose-6-phosphate dehydrogenase) into the genome under the control of PAOX1 via homologous recombination, and introduction and genomic integration of ARO4K229L (3-deoxy-D-arabino-heptulosonate-7-phosphate synthase) and ARO7G141S (chorismate mutase) from S. cerevisiae at the AOX1 promoter locus driven by homologous recombination. This strain was further engineered to produce 1067 mg/L naringenin and 1825 mg/L eriodictyol via introduction of the relevant synthetic pathways, representing the most efficient production reported to date [96]. P. pastoris also supports the bio-production of alcohols and organic acids. Isopentanol biosynthesis requires 2-ketoisocaproate (2-KIC) as a key precursor. The accumulation of 2-KIC was promoted by overexpressing the endogenous valine and lysine biosynthesis pathways via an increase in the genomic copy numbers of the relative genes. Moreover, the keto-acid degradation pathway was expressed via genomic integration of LlkivD from Lactococcus lactis (encoding ketoisovalerate decarboxylase) and ScADH7 from S. cerevisiae (encoding alcohol dehydrogenase 7) using homologous recombination, thus increasing the conversion of 2-KIC to isopentanol. Furthermore, PDC (encoding pyruvate decarboxylase) was deleted using CRISPR/Cas9 to reduce the formation of the byproduct ethanol. Finally, isopentanol was produced at 191 mg/L [98].

6. Conclusions and Prospects

Pichia pastoris has been developed to produce proteins for four decades and has emerged as a new chassis to produce diverse chemicals and natural products in recent years. With the unique property of utilizing methanol as a sole carbon source, metabolic engineering of P. pastoris is attracting increasing attention amid the great concern on global energy security, given the potential of methanol as a supply of energy and carbon source for biomanufacturing. P. pastoris has shown great success in the biosynthesis of some natural products with the titers reaching >1 g/L, indicating very promising applications for industrialization and commercialization. However, some issues are still present in P. pastoris, which hinder dedicated metabolic engineering of this microbe towards higher competence for on-demand production of chemicals and natural products. Firstly, extensive exploration of metabolic pathways is severely needed for their involvement in natural product biosynthesis, such as the mevalonate biosynthetic pathway, aromatic amino acid biosynthetic pathway, and so on. At present, the genome-scale model of P. pastoris is available but there is still very limited information on the details of metabolic flux distribution; in addition, more studies are required via the integration of multi-dimensional systems biology approaches with omics data and mathematical models to unveil potential gene targets responsible for the rearrangement of metabolic flux, especially for the accumulation of key precursors such as acetyl-CoA, malonyl-CoA, and dimethylallyl pyrophosphate. Secondly, enabling technologies and tools are not well developed. Although the CRISPR-based genome editing tool is available for P. pastoris, the current tools and genetic elements for metabolic engineering of P. pastoris are severely insufficient compared to its counterpart model strains including S. cerevisiae, E. coli, and other microorganisms. Future investigations are required to develop more tools such as promoter libraries, UTR sequences, terminator sequences, genomic sites for gene integration, dynamic regulation tools, and other genetic materials. Owing to the development of RNA-seq, single-cell analysis, and high-throughput analysis, it is convenient to develop tools for the use in genetic modification of P. pastoris. Moreover, artificial intelligence (AI) has been empowering metabolic engineering and synthetic biology, and construction of highly efficient strains can be accomplished precisely and efficiently compared to the routinely used time-consuming processes. All these technical achievements will definitely lead to an expanded spectrum of bio-products that can be synthesized at acceptable levels in engineered P. pastoris cell factories.

Author Contributions

Conceptualization, J.Z. and X.W.; Writing, J.Z., D.L., J.R., Z.L., and X.W.; Funding Acquisition, J.Z. and X.W.; All authors have read and agreed to the published version of the manuscript.

Funding

We acknowledge the financial support from the National Natural Science Foundation of China (32170175), the Key Research and Development Program of Shaanxi (2023-YBSF-260), and the Xi’an Science and Technology Plan Project (22GXFW0015).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kurtzman, C.P. Biotechnological strains of Komagataella (Pichia) pastoris are Komagataella phaffii as determined from multigene sequence analysis. J. Ind. Microbiol. Biotechnol. 2009, 36, 1435–1438. [Google Scholar] [CrossRef] [PubMed]
  2. Kulagina, N.; Besseau, S.; Godon, C.; Goldman, G.H.; Papon, N.; Courdavault, V. Yeasts as biopharmaceutical production platforms. Front. Fungal Biol. 2021, 2, 733492. [Google Scholar] [CrossRef]
  3. Cereghino, G.P.L.; Cereghino, J.L.; Ilgen, C.; Cregg, J.M. Production of recombinant proteins in fermenter cultures of the yeast Pichia pastoris. Curr. Opin. Biotechnol. 2002, 13, 329–332. [Google Scholar] [CrossRef] [PubMed]
  4. Cereghino, J.L.; Cregg, J.M. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol. Rev. 2000, 24, 45–66. [Google Scholar] [CrossRef] [PubMed]
  5. Hasslacher, M.; Schall, M.; Hayn, M.; Bona, R.; Rumbold, K.; Lückl, J.; Griengl, H.; Kohlwein, S.D.; Schwab, H. High-level intracellular expression of hydroxynitrile lyase from the tropical rubber tree Hevea brasiliensis in microbial hosts. Protein Expr. Purif. 1997, 11, 61–71. [Google Scholar] [CrossRef]
  6. Karbalaei, M.; Rezaee, S.A.; Farsiani, H. Pichia pastoris: A highly successful expression system for optimal synthesis of heterologous proteins. J. Cell Physiol. 2020, 235, 5867–5881. [Google Scholar] [CrossRef]
  7. Pan, Y.; Yang, J.; Wu, J.; Yang, L.; Fang, H. Current advances of Pichia pastoris as cell factories for production of recombinant proteins. Front. Microbiol. 2022, 13, 1059777. [Google Scholar] [CrossRef]
  8. Gao, J.; Jiang, L.; Lian, J. Development of synthetic biology tools to engineer Pichia pastoris as a chassis for the production of natural products. Synth. Syst. Biotechnol. 2021, 6, 110–119. [Google Scholar] [CrossRef]
  9. Grinna, L.S.; Tschopp, J.F. Size distribution and general structural features of N-linked oligosaccharides from the methylotrophic yeast, Pichia pastoris. Yeast 1989, 5, 107–115. [Google Scholar] [CrossRef]
  10. Zhu, T.; Zhao, T.; Bankefa, O.E.; Li, Y. Engineering unnatural methylotrophic cell factories for methanol-based biomanufacturing: Challenges and opportunities. Biotechnol. Adv. 2020, 39, 107467. [Google Scholar] [CrossRef]
  11. Cai, P.; Duan, X.; Wu, X.; Gao, L.; Ye, M.; Zhou, Y.J. Recombination machinery engineering facilitates metabolic engineering of the industrial yeast Pichia pastoris. Nucleic Acids Res. 2021, 49, 7791–7805. [Google Scholar] [CrossRef] [PubMed]
  12. Schwarzhans, J.-P.; Luttermann, T.; Geier, M.; Kalinowski, J.; Friehs, K. Towards systems metabolic engineering in Pichia pastoris. Biotechnol. Adv. 2017, 35, 681–710. [Google Scholar] [CrossRef] [PubMed]
  13. Shrivastava, A.; Pal, M.; Sharma, R.K. Pichia as yeast cell factory for production of industrially important bio-products: Current trends, challenges, and future prospects. J. Bioresour. Bioprod. 2023, 8, 108–124. [Google Scholar] [CrossRef]
  14. Batt, C.A. Pichia pastoris. In Encyclopedia of Food Microbiology; Academic Press: London, UK, 2014; pp. 42–46. [Google Scholar] [CrossRef]
  15. Heistinger, L.; Moser, J.; Tatto, N.E.; Valli, M.; Gasser, B.; Mattanovich, D. Identification and characterization of the Komagataella phaffii mating pheromone genes. FEMS Yeast Res. 2018, 18, foy051. [Google Scholar] [CrossRef] [PubMed]
  16. Dragosits, M.; Stadlmann, J.; Albiol, J.; Baumann, K.; Maurer, M.; Gasser, B.; Sauer, M.; Altmann, F.; Ferrer, P.; Mattanovich, D. The effect of temperature on the proteome of recombinant Pichia pastoris. J. Proteome Res. 2009, 8, 1380–1392. [Google Scholar] [CrossRef] [PubMed]
  17. Rosenbergová, Z.; Kántorová, K.; Šimkovič, M.; Breier, A.; Rebroš, M. Optimisation of recombinant myrosinase production in Pichia pastoris. Int. J. Mol. Sci. 2021, 22, 3677. [Google Scholar] [CrossRef] [PubMed]
  18. Ata, Ö.; Rebnegger, C.; Tatto, N.E.; Valli, M.; Mairinger, T.; Hann, S.; Steiger, M.G.; Çalık, P.; Mattanovich, D. A single Gal4-like transcription factor activates the Crabtree effect in Komagataella phaffii. Nat. Commun. 2018, 9, 4911. [Google Scholar] [CrossRef]
  19. Zhan, C.; Wang, S.; Sun, Y.; Dai, X.; Liu, X.; Harvey, L.; McNeil, B.; Yang, Y.; Bai, Z. The Pichia pastoris transmembrane protein GT1 is a glycerol transporter and relieves the repression of glycerol on AOX1 expression. FEMS Yeast Res. 2016, 16, fow033. [Google Scholar] [CrossRef]
  20. Liu, B.; Zhang, Y.; Zhang, X.; Yan, C.; Zhang, Y.; Xu, X.; Zhang, W. Discovery of a rhamnose utilization pathway and rhamnose-inducible promoters in Pichia pastoris. Sci. Rep. 2016, 6, 27352. [Google Scholar] [CrossRef]
  21. Liu, B.; Li, H.; Zhou, H.; Zhang, J. Enhancing xylanase expression by Komagataella phaffii by formate as carbon source and inducer. Appl. Microbiol. Biotechnol. 2022, 106, 7819–7829. [Google Scholar] [CrossRef]
  22. Gabaldón, T. Peroxisome diversity and evolution. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2010, 365, 765–773. [Google Scholar] [CrossRef] [PubMed]
  23. Vogl, T.; Glieder, A. Regulation of Pichia pastoris promoters and its consequences for protein production. New Biotechnol. 2013, 30, 385–404. [Google Scholar] [CrossRef] [PubMed]
  24. Yu, X.-W.; Lu, X.; Zhao, L.-S.; Xu, Y. Impact of NH4+ nitrogen source on the production of Rhizopus oryzae lipase in Pichia pastoris. Process Biochem. 2013, 48, 1462–1468. [Google Scholar] [CrossRef]
  25. Rumjantsev, A.M.; Bondareva, O.V.; Padkina, M.V.; Sambuk, E.V. Effect of nitrogen source and inorganic phosphate concentration on methanol utilization and PEX genes expression in Pichia pastoris. Sci. World J. 2014, 2014, 743615. [Google Scholar] [CrossRef]
  26. Ayed, A.; Rabhi, I.; Dellagi, K.; Kallel, H. High level production and purification of human interferon α2b in high cell density culture of Pichia pastoris. Enzym. Microb. Technol. 2008, 42, 173–180. [Google Scholar] [CrossRef]
  27. Ahmad, M.; Hirz, M.; Pichler, H.; Schwab, H. Protein expression in Pichia pastoris: Recent achievements and perspectives for heterologous protein production. Appl. Microbiol. Biotechnol. 2014, 98, 5301–5317. [Google Scholar] [CrossRef]
  28. Barone, G.D.; Emmerstorfer-Augustin, A.; Biundo, A.; Pisano, I.; Coccetti, P.; Mapelli, V.; Camattari, A. Industrial production of proteins with Pichia pastoris-Komagataella phaffii. Biomolecules 2023, 13, 441. [Google Scholar] [CrossRef]
  29. Gleeson, M.A.; White, C.E.; Meininger, D.P.; Komives, E.A. Generation of protease-deficient strains and their use in heterologous protein expression. Methods Mol. Biol. 1998, 103, 81–94. [Google Scholar] [CrossRef]
  30. Brady, J.R.; Whittaker, C.A.; Tan, M.C.; Kristensen, D.L.; Ma, D.; Dalvie, N.C.; Love, K.R.; Love, J.C. Comparative genome-scale analysis of Pichia pastoris variants informs selection of an optimal base strain. Biotechnol. Bioeng. 2020, 117, 543–555. [Google Scholar] [CrossRef]
  31. Vijayakumar, V.E.; Venkataraman, K. A Systematic review of the potential of Pichia pastoris (Komagataella phaffii) as an alternative host for biologics production. Mol. Biotechnol. 2023, 1–19. [Google Scholar] [CrossRef]
  32. Nakamura, Y.; Nishi, T.; Noguchi, R.; Ito, Y.; Watanabe, T.; Nishiyama, T.; Aikawa, S.; Hasunuma, T.; Ishii, J.; Okubo, Y.; et al. A Stable, Autonomously Replicating Plasmid Vector C containing Pichia pastoris centromeric DNA. Appl. Envion. Microbiol. 2018, 84, e02882-17. [Google Scholar] [CrossRef] [PubMed]
  33. Gu, Y.; Gao, J.; Cao, M.; Dong, C.; Lian, J.; Huang, L.; Cai, J.; Xu, Z. Construction of a series of episomal plasmids and their application in the development of an efficient CRISPR/Cas9 system in Pichia pastoris. World J. Microbiol. Biotechnol. 2019, 35, 79. [Google Scholar] [CrossRef]
  34. Inan, M. Studies on the Alcohol Oxidase (AOX1) Promoter of Pichia pastoris; The University of Nebraska: Lincoln, NE, USA, 2000. [Google Scholar]
  35. Wang, X.; Wang, Q.; Wang, J.; Bai, P.; Shi, L.; Shen, W.; Zhou, M.; Zhou, X.; Zhang, Y.; Cai, M. Mit1 transcription factor mediates methanol signaling and regulates the Alcohol Oxidase 1 (AOX1) Promoter in Pichia pastoris. J. Biol. Chem. 2016, 291, 6245–6261. [Google Scholar] [CrossRef]
  36. Haghighi Poodeh, S.; Ranaei Siadat, S.O.; Arjmand, S.; Khalifeh Soltani, M. Improving AOX1 promoter efficiency by overexpression of Mit1 transcription factor. Mol. Biol. Rep. 2022, 49, 9379–9386. [Google Scholar] [CrossRef] [PubMed]
  37. Sahu, U.; Krishna Rao, K.; Rangarajan, P.N. Trm1p, a Zn(II)2Cys6-type transcription factor, is essential for the transcriptional activation of genes of methanol utilization pathway, in Pichia pastoris. Biochem. Biophys. Res. Commun. 2014, 451, 158–164. [Google Scholar] [CrossRef] [PubMed]
  38. Waterham, H.R.; Digan, M.E.; Koutz, P.J.; Lair, S.V.; Cregg, J.M. Isolation of the Pichia pastoris glyceraldehyde-3-phosphate dehydrogenase gene and regulation and use of its promoter. Gene 1997, 186, 37–44. [Google Scholar] [CrossRef] [PubMed]
  39. Garrigós-Martínez, J.; Vuoristo, K.; Nieto-Taype, M.A.; Tähtiharju, J.; Uusitalo, J.; Tukiainen, P.; Schmid, C.; Tolstorukov, I.; Madden, K.; Penttilä, M.; et al. Bioprocess performance analysis of novel methanol-independent promoters for recombinant protein production with Pichia pastoris. Microb. Cell Factories 2021, 20, 74. [Google Scholar] [CrossRef]
  40. Baghban, R.; Farajnia, S.; Ghasemi, Y.; Mortazavi, M.; Zarghami, N.; Samadi, N. New developments in Pichia pastoris expression system, review and update. Curr. Pharm. Biotechnol. 2018, 19, 451–467. [Google Scholar] [CrossRef]
  41. Döring, F.; Klapper, M.; Theis, S.; Daniel, H. Use of the glyceraldehyde-3-phosphate dehydrogenase promoter for production of functional mammalian membrane transport proteins in the yeast Pichia pastoris. Biochem. Biophys. Res. Commun. 1998, 250, 531–535. [Google Scholar] [CrossRef]
  42. Ata, Ö.; Prielhofer, R.; Gasser, B.; Mattanovich, D.; Çalık, P. Transcriptional engineering of the glyceraldehyde-3-phosphate dehydrogenase promoter for improved heterologous protein production in Pichia pastoris. Biotechnol. Bioeng. 2017, 114, 2319–2327. [Google Scholar] [CrossRef]
  43. Jiang, B.; Argyros, R.; Bukowski, J.; Nelson, S.; Sharkey, N.; Kim, S.; Copeland, V.; Davidson, R.C.; Chen, R.; Zhuang, J.; et al. Inactivation of a GAL4-like transcription factor improves cell fitness and product yield in glycoengineered Pichia pastoris strains. Appl. Envion. Microbiol. 2015, 81, 260–271. [Google Scholar] [CrossRef] [PubMed]
  44. Wang, J.; Wang, X.; Shi, L.; Qi, F.; Zhang, P.; Zhang, Y.; Zhou, X.; Song, Z.; Cai, M. Methanol-independent protein expression by AOX1 Promoter with trans-acting elements engineering and glucose-glycerol-shift induction in Pichia pastoris. Sci. Rep. 2017, 7, 41850. [Google Scholar] [CrossRef] [PubMed]
  45. Chang, C.-H.; Hsiung, H.-A.; Hong, K.-L.; Huang, C.-T. Enhancing the efficiency of the Pichia pastoris AOX1 promoter via the synthetic positive feedback circuit of transcription factor Mxr1. BMC Biotechnol. 2018, 18, 81. [Google Scholar] [CrossRef] [PubMed]
  46. Shen, W.; Kong, C.; Xue, Y.; Liu, Y.; Cai, M.; Zhang, Y.; Jiang, T.; Zhou, X.; Zhou, M. Kinase screening in Pichia pastoris identified promising targets involved in cell growth and Alcohol Oxidase 1 promoter (PAOX1) regulation. PLoS ONE 2016, 11, e0167766. [Google Scholar] [CrossRef] [PubMed]
  47. Shen, W.; Xue, Y.; Liu, Y.; Kong, C.; Wang, X.; Huang, M.; Cai, M.; Zhou, X.; Zhang, Y.; Zhou, M. A novel methanol-free Pichia pastoris system for recombinant protein expression. Microb. Cell Factories 2016, 15, 178. [Google Scholar] [CrossRef] [PubMed]
  48. Dou, W.; Zhu, Q.; Zhang, M.; Jia, Z.; Guan, W. Screening and evaluation of the strong endogenous promoters in Pichia pastoris. Microb. Cell Factories 2021, 20, 156. [Google Scholar] [CrossRef]
  49. Zhang, Y.; Wang, S.; Lu, L.; Zhang, C.; Cai, F.; Lin, Y.; Huang, Y. Isolation and evaluation of strong endogenous promoters for the heterologous expression of proteins in Pichia pastoris. World J. Microbiol. Biotechnol. 2022, 38, 226. [Google Scholar] [CrossRef]
  50. Erden-Karaoğlan, F.; Karaoğlan, M. Applicability of the heterologous yeast promoters for recombinant protein production in Pichia pastoris. Appl. Microbiol. Biotechnol. 2022, 106, 7073–7083. [Google Scholar] [CrossRef]
  51. Erden-Karaoğlan, F.; Karaoğlan, M.; Yılmaz, G.; Yılmaz, S.; İnan, M. Deletion analysis of Pichia pastoris alcohol dehydrogenase 2 (ADH2) promoter and development of synthetic promoters. Biotechnol. J. 2022, 17, e2100332. [Google Scholar] [CrossRef]
  52. Nong, L.; Zhang, Y.; Duan, Y.; Hu, S.; Lin, Y.; Liang, S. Engineering the regulatory site of the catalase promoter for improved heterologous protein production in Pichia pastoris. Biotechnol. Lett. 2020, 42, 2703–2709. [Google Scholar] [CrossRef]
  53. Karaoglan, M.; Karaoglan, F.E.; Inan, M. Comparison of ADH3 promoter with commonly used promoters for recombinant protein production in Pichia pastoris. Protein Expr. Purif. 2016, 121, 112–117. [Google Scholar] [CrossRef] [PubMed]
  54. Resina, D.; Cos, O.; Ferrer, P.; Valero, F. Developing high cell density fed-batch cultivation strategies for heterologous protein production in Pichia pastoris using the nitrogen source-regulated FLD1 Promoter. Biotechnol. Bioeng. 2005, 91, 760–767. [Google Scholar] [CrossRef] [PubMed]
  55. Kranthi, B.V.; Kumar, H.R.V.; Rangarajan, P.N. Identification of Mxr1p-binding sites in the promoters of genes encoding dihydroxyacetone synthase and peroxin 8 of the methylotrophic yeast Pichia pastoris. Yeast 2010, 27, 705–711. [Google Scholar] [CrossRef] [PubMed]
  56. Prielhofer, R.; Reichinger, M.; Wagner, N.; Claes, K.; Kiziak, C.; Gasser, B.; Mattanovich, D. Superior protein titers in half the fermentation time: Promoter and process engineering for the glucose-regulated GTH1 promoter of Pichia pastoris. Biotechnol. Bioeng. 2018, 115, 2479–2488. [Google Scholar] [CrossRef] [PubMed]
  57. Tschopp, J.F.; Brust, P.F.; Cregg, J.M.; Stillman, C.A.; Gingeras, T.R. Expression of the lacZ gene from two methanol-regulated promoters in Pichia pastoris. Nucleic Acids Res. 1987, 15, 3859–3876. [Google Scholar] [CrossRef]
  58. Liang, S.; Zou, C.; Lin, Y.; Zhang, X.; Ye, Y. Identification and characterization of PGCW14: A novel, strong constitutive promoter of Pichia pastoris. Biotechnol. Lett. 2013, 35, 1865–1871. [Google Scholar] [CrossRef]
  59. Vogl, T.; Ruth, C.; Pitzer, J.; Kickenweiz, T.; Glieder, A. Synthetic core promoters for Pichia pastoris. ACS Synth. Biol. 2014, 3, 188–191. [Google Scholar] [CrossRef]
  60. Portela, R.M.C.; Vogl, T.; Kniely, C.; Fischer, J.E.; Oliveira, R.; Glieder, A. Synthetic core promoters as universal parts for fine-tuning expression in different yeast species. ACS Synth. Biol. 2017, 6, 471–484. [Google Scholar] [CrossRef]
  61. Damasceno, L.M.; Anderson, K.A.; Ritter, G.; Cregg, J.M.; Old, L.J.; Batt, C.A. Cooverexpression of chaperones for enhanced secretion of a single-chain antibody fragment in Pichia pastoris. Appl. Microbiol. Biotechnol. 2007, 74, 381–389. [Google Scholar] [CrossRef]
  62. Owji, H.; Nezafat, N.; Negahdaripour, M.; Hajiebrahimi, A.; Ghasemi, Y. A comprehensive review of signal peptides: Structure, roles, and applications. Eur. J. Cell Biol. 2018, 97, 422–441. [Google Scholar] [CrossRef]
  63. Ahn, J.; Jang, M.J.; Ang, K.S.; Lee, H.; Choi, E.S.; Lee, D.Y. Codon optimization of Saccharomyces cerevisiae mating factor alpha prepro-leader to improve recombinant protein production in Pichia pastoris. Biotechnol. Lett. 2016, 38, 2137–2143. [Google Scholar] [CrossRef] [PubMed]
  64. Barrero, J.J.; Casler, J.C.; Valero, F.; Ferrer, P.; Glick, B.S. An improved secretion signal enhances the secretion of model proteins from Pichia pastoris. Microb. Cell Factories 2018, 17, 161. [Google Scholar] [CrossRef] [PubMed]
  65. Ito, Y.; Ishigami, M.; Hashiba, N.; Nakamura, Y.; Terai, G.; Hasunuma, T.; Ishii, J.; Kondo, A. Avoiding entry into intracellular protein degradation pathways by signal mutations increases protein secretion in Pichia pastoris. Microb. Biotechnol. 2022, 15, 2364–2378. [Google Scholar] [CrossRef] [PubMed]
  66. Duan, G.; Ding, L.; Wei, D.; Zhou, H.; Chu, J.; Zhang, S.; Qian, J. Screening endogenous signal peptides and protein folding factors to promote the secretory expression of heterologous proteins in Pichia pastoris. J. Biotechnol. 2019, 306, 193–202. [Google Scholar] [CrossRef]
  67. Xiong, R.; Chen, J.; Chen, J. Secreted expression of human lysozyme in the yeast Pichia pastoris under the direction of the signal peptide from human serum albumin. Biotechnol. Appl. Biochem. 2008, 51, 129–134. [Google Scholar] [CrossRef]
  68. Vadhana, A.K.P.; Samuel, P.; Berin, R.M.; Krishna, J.; Kamatchi, K.; Meenakshisundaram, S. Improved secretion of Candida antarctica lipase B with its native signal peptide in Pichia pastoris. Enzym. Microb. Technol. 2013, 52, 177–183. [Google Scholar] [CrossRef]
  69. Peña, D.A.; Gasser, B.; Zanghellini, J.; Steiger, M.G.; Mattanovich, D. Metabolic engineering of Pichia pastoris. Metab. Eng. 2018, 50, 2–15. [Google Scholar] [CrossRef]
  70. Wu, X.; Cai, P.; Yao, L.; Zhou, Y.J. Genetic tools for metabolic engineering of Pichia pastoris. Eng. Microbiol. 2023, 3, 100094. [Google Scholar] [CrossRef]
  71. Weninger, A.; Hatzl, A.-M.; Schmid, C.; Vogl, T.; Glieder, A. Combinatorial optimization of CRISPR/Cas9 expression enables precision genome engineering in the methylotrophic yeast Pichia pastoris. J. Biotechnol. 2016, 235, 139–149. [Google Scholar] [CrossRef]
  72. Weninger, A.; Fischer, J.E.; Raschmanová, H.; Kniely, C.; Vogl, T.; Glieder, A. Expanding the CRISPR/Cas9 toolkit for Pichia pastoris with efficient donor integration and alternative resistance markers. J. Cell Biochem. 2018, 119, 3183–3198. [Google Scholar] [CrossRef]
  73. Liu, Q.; Shi, X.; Song, L.; Liu, H.; Zhou, X.; Wang, Q.; Zhang, Y.; Cai, M. CRISPR-Cas9-mediated genomic multiloci integration in Pichia pastoris. Microb. Cell Factories 2019, 18, 144. [Google Scholar] [CrossRef] [PubMed]
  74. Gao, J.; Xu, J.; Zuo, Y.; Ye, C.; Jiang, L.; Feng, L.; Huang, L.; Xu, Z.; Lian, J. Synthetic biology toolkit for marker-less integration of multigene pathways into Pichia pastoris via CRISPR/Cas9. ACS Synth. Biol. 2022, 11, 623–633. [Google Scholar] [CrossRef]
  75. Gao, J.; Ye, C.; Cheng, J.; Jiang, L.; Yuan, X.; Lian, J. Enhancing homologous recombination efficiency in Pichia pastoris for multiplex genome integration using short homology arms. ACS Synth. Biol. 2022, 11, 547–553. [Google Scholar] [CrossRef] [PubMed]
  76. Sandberg, T.E.; Salazar, M.J.; Weng, L.L.; Palsson, B.O.; Feist, A.M. The emergence of adaptive laboratory evolution as an efficient tool for biological discovery and industrial biotechnology. Metab. Eng. 2019, 56, 1–16. [Google Scholar] [CrossRef]
  77. Hirasawa, T.; Maeda, T. Adaptive laboratory evolution of microorganisms: Methodology and application for bioproduction. Microorganisms 2022, 11, 92. [Google Scholar] [CrossRef] [PubMed]
  78. Lee, S.; Kim, P. Current status and applications of adaptive laboratory evolution in industrial microorganisms. J. Microbiol. Biotechnol. 2020, 30, 793–803. [Google Scholar] [CrossRef]
  79. Moser, J.W.; Prielhofer, R.; Gerner, S.M.; Graf, A.B.; Wilson, I.B.H.; Mattanovich, D.; Dragosits, M. Implications of evolutionary engineering for growth and recombinant protein production in methanol-based growth media in the yeast Pichia pastoris. Microb. Cell Factories 2017, 16, 49. [Google Scholar] [CrossRef] [PubMed]
  80. Bankefa, O.E.; Samuel-Osamoka, F.C.; Oladeji, S.J. Improved enzyme production on corncob hydrolysate by a xylose-evolved Pichia pastoris cell factory. J. Food Sci. Technol. 2022, 59, 1280–1287. [Google Scholar] [CrossRef]
  81. Gassler, T.; Sauer, M.; Gasser, B.; Egermeier, M.; Troyer, C.; Causon, T.; Hann, S.; Mattanovich, D.; Steiger, M.G. The industrial yeast Pichia pastoris is converted from a heterotroph into an autotroph capable of growth on CO2. Nat. Biotechnol. 2020, 38, 210–216. [Google Scholar] [CrossRef]
  82. Gassler, T.; Baumschabl, M.; Sallaberger, J.; Egermeier, M.; Mattanovich, D. Adaptive laboratory evolution and reverse engineering enhances autotrophic growth in Pichia pastoris. Metab. Eng. 2022, 69, 112–121. [Google Scholar] [CrossRef]
  83. Higgins, D.R.; Cregg, J.M. Introduction to Pichia pastoris. Methods Mol. Biol. 1998, 103, 1–15. [Google Scholar] [CrossRef] [PubMed]
  84. Damasceno, L.M.; Huang, C., Jr.; Batt, C.A. Protein secretion in Pichia pastoris and advances in protein production. Appl. Microbiol. Biotechnol. 2012, 93, 31–39. [Google Scholar] [CrossRef] [PubMed]
  85. Zuo, Y.; Xiao, F.; Gao, J.; Ye, C.; Jiang, L.; Dong, C.; Lian, J. Establishing Komagataella phaffii as a cell factory for efficient production of sesquiterpenoid α-Santalene. J. Agric. Food Chem. 2022, 70, 8024–8031. [Google Scholar] [CrossRef] [PubMed]
  86. Gao, J.; Zuo, Y.; Xiao, F.; Wang, Y.; Li, D.; Xu, J.; Ye, C.; Feng, L.; Jiang, L.; Liu, T.; et al. Biosynthesis of catharanthine in engineered Pichia pastoris. Nat. Synth. 2023, 2, 231–242. [Google Scholar] [CrossRef]
  87. Zhang, X.; Wang, D.; Duan, Y.; Zheng, X.; Lin, Y.; Liang, S. Production of lycopene by metabolically engineered Pichia pastoris. Biosci. Biotechnol. Biochem. 2020, 84, 463–470. [Google Scholar] [CrossRef]
  88. Chen, S.-L.; Liu, T.-S.; Zhang, W.-G.; Xu, J.-Z. Cofactor engineering for efficient production of α-Farnesene by rational modification of NADPH and ATP regeneration pathway in Pichia pastoris. Int. J. Mol. Sci. 2023, 24, 1767. [Google Scholar] [CrossRef]
  89. Jeong, E.; Shim, W.Y.; Kim, J.H. Metabolic engineering of Pichia pastoris for production of hyaluronic acid with high molecular weight. J. Biotechnol. 2014, 185, 28–36. [Google Scholar] [CrossRef]
  90. Jin, X.; Zhang, W.; Wang, Y.; Sheng, J.; Xu, R.; Li, J.; Du, G.; Kang, Z. Biosynthesis of non-animal chondroitin sulfate from methanol using genetically engineered Pichia pastoris. Green Chem. 2021, 23, 4365–4374. [Google Scholar] [CrossRef]
  91. Qian, D.; Zhang, C.; Deng, C.; Zhou, M.; Fan, L.; Zhao, L. De novo biosynthesis of 2′-fucosyllactose in engineered Pichia pastoris. Biotechnol. Lett. 2023, 45, 521–536. [Google Scholar] [CrossRef]
  92. Gao, L.; Cai, M.; Shen, W.; Xiao, S.; Zhou, X.; Zhang, Y. Engineered fungal polyketide biosynthesis in Pichia pastoris: A potential excellent host for polyketide production. Microb. Cell Factories 2013, 12, 77. [Google Scholar] [CrossRef]
  93. Xue, Y.; Kong, C.; Shen, W.; Bai, C.; Ren, Y.; Zhou, X.; Zhang, Y.; Cai, M. Methylotrophic yeast Pichia pastoris as a chassis organism for polyketide synthesis via the full citrinin biosynthetic pathway. J. Biotechnol. 2017, 242, 64–72. [Google Scholar] [CrossRef]
  94. Liu, Y.; Tu, X.; Xu, Q.; Bai, C.; Kong, C.; Liu, Q.; Yu, J.; Peng, Q.; Zhou, X.; Zhang, Y.; et al. Engineered monoculture and co-culture of methylotrophic yeast for de novo production of monacolin J and lovastatin from methanol. Metab. Eng. 2018, 45, 189–199. [Google Scholar] [CrossRef]
  95. Qian, Z.; Yu, J.; Chen, X.; Kang, Y.; Ren, Y.; Liu, Q.; Lu, J.; Zhao, Q.; Cai, M. De novo production of plant 4′-Deoxyflavones baicalein and oroxylin A from ethanol in Crabtree-negative yeast. ACS Synth. Biol. 2022, 11, 1600–1612. [Google Scholar] [CrossRef] [PubMed]
  96. Kumokita, R.; Bamba, T.; Inokuma, K.; Yoshida, T.; Ito, Y.; Kondo, A.; Hasunuma, T. Construction of an L-Tyrosine chassis in Pichia pastoris enhances aromatic secondary metabolite production from glycerol. ACS Synth. Biol. 2022, 11, 2098–2107. [Google Scholar] [CrossRef] [PubMed]
  97. Bumrungtham, P.; Promdonkoy, P.; Prabmark, K.; Bunterngsook, B.; Boonyapakron, K.; Tanapongpipat, S.; Champreda, V.; Runguphan, W. Engineered production of isobutanol from sugarcane trash hydrolysates in Pichia pastoris. J. Fungi 2022, 8, 767. [Google Scholar] [CrossRef] [PubMed]
  98. Siripong, W.; Angela, C.; Tanapongpipat, S.; Runguphan, W. Metabolic engineering of Pichia pastoris for production of isopentanol (3-Methyl-1-butanol). Enzym. Microb. Technol. 2020, 138, 109557. [Google Scholar] [CrossRef]
  99. Guo, F.; Dai, Z.; Peng, W.; Zhang, S.; Zhou, J.; Ma, J.; Dong, W.; Xin, F.; Zhang, W.; Jiang, M. Metabolic engineering of Pichia pastoris for malic acid production from methanol. Biotechnol. Bioeng. 2021, 118, 357–371. [Google Scholar] [CrossRef]
  100. Hamers-Casterman, C.; Atarhouch, T.; Muyldermans, S.; Robinson, G.; Hamers, C.; Songa, E.B.; Bendahman, N.; Hamers, R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363, 446–448. [Google Scholar] [CrossRef]
  101. Greenberg, A.S.; Avila, D.; Hughes, M.; Hughes, A.; McKinney, E.C.; Flajnik, M.F. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 1995, 374, 168–173. [Google Scholar] [CrossRef]
  102. Hassanzadeh-Ghassabeh, G.; Devoogdt, N.; De Pauw, P.; Vincke, C.; Muyldermans, S. Nanobodies and their potential applications. Nanomedicine 2013, 8, 1013–1026. [Google Scholar] [CrossRef]
  103. Huo, J.; Mikolajek, H.; Le Bas, A.; Clark, J.J.; Sharma, P.; Kipar, A.; Dormon, J.; Norman, C.; Weckener, M.; Clare, D.K.; et al. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. Nat. Commun. 2021, 12, 5469. [Google Scholar] [CrossRef] [PubMed]
  104. Muyldermans, S. A guide to: Generation and design of nanobodies. FEBS J. 2021, 288, 2084–2102. [Google Scholar] [CrossRef]
  105. Baghban, R.; Gargari, S.L.M.; Rajabibazl, M.; Nazarian, S.; Bakherad, H. Camelid-derived heavy-chain nanobody against Clostridium botulinum neurotoxin E in Pichia pastoris. Biotechnol. Appl. Biochem. 2016, 63, 200–205. [Google Scholar] [CrossRef] [PubMed]
  106. Xian, Z.; Ma, L.; Zhu, M.; Li, G.; Gai, J.; Chang, Q.; Huang, Y.; Ju, D.; Wan, Y. Blocking the PD-1-PD-L1 axis by a novel PD-1 specific nanobody expressed in yeast as a potential therapeutic for immunotherapy. Biochem. Biophys. Res. Commun. 2019, 519, 267–273. [Google Scholar] [CrossRef]
  107. Chen, Q.; Zhou, Y.; Yu, J.; Liu, W.; Li, F.; Xian, M.; Nian, R.; Song, H.; Feng, D. An efficient constitutive expression system for Anti-CEACAM5 nanobody production in the yeast Pichia pastoris. Protein Expr. Purif. 2019, 155, 43–47. [Google Scholar] [CrossRef] [PubMed]
  108. Xu, Z.; Qiu, C.; Wen, B.; Wang, S.; Zhu, L.; Zhao, L.; Li, H. A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo. Biochem. Biophys. Res. Commun. 2021, 548, 78–83. [Google Scholar] [CrossRef]
  109. Zhu, W.; Gong, G.; Pan, J.; Han, S.; Zhang, W.; Hu, Y.; Xie, L. High level expression and purification of recombinant human serum albumin in Pichia pastoris. Protein Expr. Purif. 2018, 147, 61–68. [Google Scholar] [CrossRef]
  110. Peng, B.; Xue, G.; Xu, D.; Feng, Z.; Chen, J.; Huang, M.; Lu, H.; Gong, L. Expression and purification of recombinant serine protease domain of human coagulation factor XII in Pichia pastoris. Biosci. Biotechnol. Biochem. 2019, 83, 1815–1821. [Google Scholar] [CrossRef]
  111. Cai, H.; Yao, H.; Li, T.; Tang, Y.; Li, D. High-level heterologous expression of the human transmembrane sterol Δ8,Δ7-isomerase in Pichia pastoris. Protein Expr. Purif. 2019, 164, 105463. [Google Scholar] [CrossRef]
  112. Gurramkonda, C.; Polez, S.; Skoko, N.; Adnan, A.; Gäbel, T.; Chugh, D.; Swaminathan, S.; Khanna, N.; Tisminetzky, S.; Rinas, U. Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulin. Microb. Cell Factories 2010, 9, 31. [Google Scholar] [CrossRef]
  113. Polez, S.; Origi, D.; Zahariev, S.; Guarnaccia, C.; Tisminetzky, S.G.; Skoko, N.; Baralle, M. A simplified and efficient process for insulin production in Pichia pastoris. PLoS ONE 2016, 11, e0167207. [Google Scholar] [CrossRef] [PubMed]
  114. Katla, S.; Karmakar, B.; Tadi, S.R.R.; Mohan, N.; Anand, B.; Pal, U.; Sivaprakasam, S. High level extracellular production of recombinant human interferon alpha 2b in glycoengineered Pichia pastoris: Culture medium optimization, high cell density cultivation and biological characterization. J. Appl. Microbiol. 2019, 126, 1438–1453. [Google Scholar] [CrossRef] [PubMed]
  115. Tholl, D. Biosynthesis and biological functions of terpenoids in plants. Adv. Biochem. Eng. Biotechnol. 2015, 148, 63–106. [Google Scholar] [CrossRef] [PubMed]
  116. Akazawa, H.; Kohno, H.; Tokuda, H.; Suzuki, N.; Yasukawa, K.; Kimura, Y.; Manosroi, A.; Manosroi, J.; Akihisa, T. Anti-inflammatory and anti-tumor-promoting effects of 5-deprenyllupulonol C and other compounds from Hop (Humulus lupulus L.). Chem. Biodivers. 2012, 9, 1045–1054. [Google Scholar] [CrossRef]
  117. Zhang, Y.; Nielsen, J.; Liu, Z. Engineering yeast metabolism for production of terpenoids for use as perfume ingredients, pharmaceuticals and biofuels. FEMS Yeast Res. 2017, 17, fox080. [Google Scholar] [CrossRef]
  118. Bhataya, A.; Schmidt-Dannert, C.; Lee, P.C. Metabolic engineering of Pichia pastoris X-33 for lycopene production. Process. Biochem. 2009, 44, 1095–1102. [Google Scholar] [CrossRef]
  119. Liu, H.; Chen, S.-L.; Xu, J.-Z.; Zhang, W.-G. Dual regulation of cytoplasm and peroxisomes for improved α-Farnesene production in recombinant Pichia pastoris. ACS Synth. Biol. 2021, 10, 1563–1573. [Google Scholar] [CrossRef]
  120. Prateeksha; Sharma, V.K.; Liu, X.; Oyarzún, D.A.; Abdel-Azeem, A.M.; Atanasov, A.G.; Hesham, A.E.-L.; Barik, S.K.; Gupta, V.K.; Singh, B.N. Microbial polysaccharides: An emerging family of natural biomaterials for cancer therapy and diagnostics. Semin. Cancer Biol. 2022, 86, 706–731. [Google Scholar] [CrossRef]
  121. Liu, L.; Liu, Y.; Li, J.; Du, G.; Chen, J. Microbial production of hyaluronic acid: Current state, challenges, and perspectives. Microb. Cell Factories 2011, 10, 99. [Google Scholar] [CrossRef]
Jof 09 01027 g001
Figure 1. Differences between Pichia pastoris and Saccharomyces cerevisiae.
Figure 1. Differences between Pichia pastoris and Saccharomyces cerevisiae.
Jof 09 01027 g001
Jof 09 01027 g002
Figure 2. Colony morphology (A) and microscopic image (B) of P. pastoris.
Figure 2. Colony morphology (A) and microscopic image (B) of P. pastoris.
Jof 09 01027 g002
Jof 09 01027 g003
Figure 3. (A) The structure of PAOX1. (B) Transcriptional regulation of PAOX1.
Figure 3. (A) The structure of PAOX1. (B) Transcriptional regulation of PAOX1.
Jof 09 01027 g003
Jof 09 01027 g004
Figure 4. The portfolio of typical compounds produced by engineered P. pastoris.
Figure 4. The portfolio of typical compounds produced by engineered P. pastoris.
Jof 09 01027 g004
Table 1. Promoters used in P. pastoris.
Table 1. Promoters used in P. pastoris.
PromotersRegulationEncoding GeneExpression LevelRefs.
PAOX1Induced by methanolAlcohol oxidaseStrong[36]
PADH2Induced by ethanolAlcohol dehydrogenaseStronger than PGAP[51]
PSNT5Induced by ethanolsynthetic promoterStrong[51]
PCAT1Induced by methanol and oleic acidCatalaseSimilar to PAOX1[52]
PLAR3Induced by L-RhamnoseL-rhamnose dehydrataseSimilar to PGAP[20]
PLAR4Induced by L-RhamnoseL-KDR aldolaseWeak[20]
PADH3Induced by ethanol and methanolAlcohol dehydrogenaseStrong[53]
PFLD1Induced by methanol and methylamineFormaldehyde dehydrogenaseSimilar to PGAP[54]
PPEX8Induced by methanolPeroxisomal matrix proteinWeak[55]
PGTH1Induced by glucoseHigh-affinity glucose transporterSimilar to PAOX1[56]
PDAS1Induced by methanolDihydroxyacetone phosphateStrong[57]
PFDH1Induced by methanolFormate dehydrogenase 1Strong[49]
PICL1Induced by ethanolIsocitrate lyase~10% of PAOX1[50]
PCUPIInduced by glucoseCopper-binding metallothionein protein~10% of PAOX1[50]
PGAPConstitutiveGlyceraldehyde-3-phosphate dehydrogenaseStrong[38]
PGCW14ConstitutiveGlycosylphosphatidylinositolStrong[58]
PTPIConstitutiveTriose phosphate isomerase~4% of PGAP[50]
PPMAConstitutivePlasma membrane (H+) ATPases~81% of PGAP[50]
Table 2. Synthesis of various compounds in P. pastoris.
Table 2. Synthesis of various compounds in P. pastoris.
ClassificationProductsTiterSynthetic StrategiesCulture ConditionsRef.
Terpenoidsα-Santalene21.5 g/LOverexpression of tHMG1 and IDI1, increase in SAS copy numberGlucose/Fermenter[85]
Catharanthine2.57 mg/LOptimization of pathway genes and integration sitesGlucose/Fermenter[86]
Lycopene6.146 mg/gPromoter selection, increase in precursor supply and GGPP accumulationMethanol/Shake flask[87]
α-Farnesene3.09 g/LPathway reconstruction for the synthesis of NADPH and ATPGlucose/Shake flask[88]
PolysaccharidesHyaluronic acid0.8–1.7 g/LInduction by PAOX2, low-temperature cultivationGlucose/Fermenter[89]
Chondroitin sulfate2.1 g/LCodon optimization, endogenous promoter analysis, enhancement of the PAPS synthesis pathwayMethanol/Fermenter[90]
2′-Fucosyllactose0.276 g/LGAP promoter controlGlucose/Fermenter[91]
Polyketides6-Methylsalicylic acid2.2 g/LHeterologous expression of atX from Aspergillus terreus and npgA from Aspergillus nidulansMethanol/Fermenter[92]
Citrinin0.6 mg/LHeterologous expression of pksCT from Monascus purpureus and npgA from Aspergillus nidulans, introduction of mpl6 and mpl7 from Monascus purpureusGlucose/Shake flask[93]
Monacolin J593.9 mg/LOptimization of pathway gene expression, co-cultureMethanol/Fermenter[94]
FlavonoidsBaicalein401.9 mg/LEthanol induction, modularization of metabolic pathwayEthanol/Shake flask[95]
Oroxylin A339.5 mg/LEthanol induction, modularization of metabolic pathwayEthanol/Shake flask[95]
Naringenin1067 mg/LOverexpression of ARO4K229L and ARO7G141S for efficient production of L-tyrosineGlycerol/Fermenter[96]
AlcoholsIsobutanol48.2 mg/LOverexpression of heterologous xylose isomerase and endogenous xylulokinase, introduction of the isobutanol pathwayGlucose/Microfermenter[97]
Isopentanol191.0 mg/LOverexpression of the endogenous valine/leucine biosynthetic pathways, and artificial keto-acid degradation pathwayGlucose/Microfermenter[98]
Organic acidsMalic acid2.79 g/LKnockout of gpi optimized methanol assimilation, optimization of nitrogen sourcesMethanol/Shake flask[99]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zha, J.; Liu, D.; Ren, J.; Liu, Z.; Wu, X. Advances in Metabolic Engineering of Pichia pastoris Strains as Powerful Cell Factories. J. Fungi 2023, 9, 1027. https://doi.org/10.3390/jof9101027

AMA Style

Zha J, Liu D, Ren J, Liu Z, Wu X. Advances in Metabolic Engineering of Pichia pastoris Strains as Powerful Cell Factories. Journal of Fungi. 2023; 9(10):1027. https://doi.org/10.3390/jof9101027

Chicago/Turabian Style

Zha, Jian, Dan Liu, Juan Ren, Zhijun Liu, and Xia Wu. 2023. "Advances in Metabolic Engineering of Pichia pastoris Strains as Powerful Cell Factories" Journal of Fungi 9, no. 10: 1027. https://doi.org/10.3390/jof9101027

APA Style

Zha, J., Liu, D., Ren, J., Liu, Z., & Wu, X. (2023). Advances in Metabolic Engineering of Pichia pastoris Strains as Powerful Cell Factories. Journal of Fungi, 9(10), 1027. https://doi.org/10.3390/jof9101027

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop